Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Norman Robert Waugh, Pamela Lee Royle, Graham Stewart Scotland, R Henderson, R Hollick, R, Paul McNamee

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


This paper presents a summary of the evidence review group (ERG) report into denosumabfor the prevention of osteoporotic fractures in postmenopausal women. Denosumab has been
shown in a large randomised trial to reduce the frequency of osteoporotic fractures when given subcutaneously at 6-monthly intervals. Compared with placebo, the relative risks of clinical
vertebral and hip fractures were 0.32 and 0.60, respectively. Clinical vertebral fractures occurred in 0.8% of women taking denosumab and 2.6% of control subjects. Hip fractures occurred in 1.2% of women on placebo and 0.7% on denosumab. The expected use is in women who cannot tolerate oral bisphosphonates. Other options in that situation include strontium ranelate and zoledronate, which, compared with placebo, also reduced the risk of clinical vertebral fractures
[relative risk (RR) 0.65 and 0.23, respectively]. Zoledronate also significantly reduced the risk of hip fractures (RR 0.59). The ERG concluded that zoledronate was the main comparator. The
relative cost-effectiveness of denosumab and zoledronate depends mainly on assumptions about costs of administration.
Original languageEnglish
Article numberHTA 08/231/01
Pages (from-to)51-59
Number of pages9
JournalHealth Technology Assessment
Issue numberSuppl. 1
Publication statusPublished - 22 Feb 2011


  • Denosumab
  • osteoporotic fractures
  • postmenopausal women


Dive into the research topics of 'Denosumab for the prevention of osteoporotic fractures in postmenopausal women'. Together they form a unique fingerprint.

Cite this